Display options
Cite
Marchetti G, Comi L, Bini T, et al. HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. J Sex Transm Dis. 2013;2013:915169doi: 10.1155/2013/915169.
Marchetti, G., Comi, L., Bini, T., Rovati, M., Bai, F., Cassani, B., Ravizza, M., Tarozzi, M., Pandolfo, A., Dalzero, S., Opocher, E., Romagnoli, S., Carrassi, A., Bosari, S., & d'Arminio Monforte, A. (2013). HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. Journal of sexually transmitted diseases, 2013915169. https://doi.org/10.1155/2013/915169
Marchetti, Giulia, et al. "HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites." Journal of sexually transmitted diseases vol. 2013 (2013): 915169. doi: https://doi.org/10.1155/2013/915169
Marchetti G, Comi L, Bini T, Rovati M, Bai F, Cassani B, Ravizza M, Tarozzi M, Pandolfo A, Dalzero S, Opocher E, Romagnoli S, Carrassi A, Bosari S, d'Arminio Monforte A. HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. J Sex Transm Dis. 2013;2013:915169. doi: 10.1155/2013/915169. Epub 2013 Mar 05. PMID: 26316967; PMCID: PMC4437419.
Copy Download .nbib Format: NLM
Share it on

J Sex Transm Dis. 2013;2013:915169. doi: 10.1155/2013/915169. Epub 2013 Mar 05.

HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites.

Journal of sexually transmitted diseases

Giulia Marchetti, Laura Comi, Teresa Bini, Marco Rovati, Francesca Bai, Barbara Cassani, Marina Ravizza, Marco Tarozzi, Alessandro Pandolfo, Serena Dalzero, Enrico Opocher, Solange Romagnoli, Antonio Carrassi, Silvano Bosari, Antonella d'Arminio Monforte

Affiliations

  1. Department of Health Sciences, Institute of Infectious and Tropical Diseases, San Paolo Hospital, University of Milan, Via A Di Rudinì 8, 20142 Milan, Italy.
  2. Surgery Chair, Department of Health Sciences, San Paolo Hospital, University of Milan, 20142 Milan, Italy.
  3. Pathology Unit, Department of Health Sciences, San Paolo Hospital, University of Milan, 20142 Milan, Italy.
  4. Department of Health Sciences, Institute of Obstetrics and Gynecology, San Paolo Hospital, University of Milan, 20142 Milan, Italy.
  5. Dentistry Chair, Department of Health Sciences, San Paolo Hospital, University of Milan, 20142 Milan, Italy.
  6. Pathology Unit, Department of Medicine, Surgery and Dentistry, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20142 Milan, Italy.

PMID: 26316967 PMCID: PMC4437419 DOI: 10.1155/2013/915169

Abstract

The aim of this study was to assess the prevalence of HPV infection and determinants of abnormal cytology in HIV-positive patients. In a cross-sectional study, patients of both sexes, asymptomatic for HPV, underwent anorectal (men)/cervical (women) and oral swabs. Cytology and HPV-PCR detection/genotyping (high- and low-risk genotypes, HR-LR/HPV) were performed. A total of 20% of the 277 enrolled patients showed oral HPV, with no atypical cytology; in men, anal HPV prevalence was 81% with 64% HR genotypes. In women, cervical HPV prevalence was 58% with 37% HR-HPV. The most frequent genotypes were HPV-16 and HPV-18; 37% of men and 20% of women harbored multiple genotypes. Also, 47% of men showed anal squamous intraepithelial lesions (SILs); 6% had high- and 35% low-grade SILs (HSILs/LSILs); 5% had atypical squamous cells of undetermined significance (ASC-US). HR-HPV was independently associated with anal-SIL in men (P = 0.039). Moreover, 37% of women showed cervical SIL: 14 ASC-US, 15 LSILs, 4 HSILs, and 1 in situ cancer. The presence of both LR and HR-HPV in women was independently associated with SIL (P = 0.003 and P = 0.0001). HR-HPV and atypical cytology were frequently identified in our cohort. HPV screening should be mandatory in HIV-infected subjects, and vaccine programs for HPV-negative patients should be implemented.

References

  1. J Gen Virol. 1991 May;72 ( Pt 5):1039-44 - PubMed
  2. J Infect Dis. 2010 Nov 15;202(10):1567-76 - PubMed
  3. BMC Infect Dis. 2011 May 25;11:150 - PubMed
  4. J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 - PubMed
  5. J Infect Dis. 2010 May 15;201(10):1498-508 - PubMed
  6. Antivir Ther. 2004 Feb;9(1):13-22 - PubMed
  7. J Infect Dis. 1998 Feb;177(2):361-7 - PubMed
  8. Am J Epidemiol. 2003 Jun 1;157(11):966-72 - PubMed
  9. AIDS. 2005 Sep 2;19(13):1407-14 - PubMed
  10. JAMA. 2001 Apr 4;285(13):1736-45 - PubMed
  11. Genitourin Med. 1997 Jun;73(3):174-80 - PubMed
  12. J Acquir Immune Defic Syndr. 2010 Jan;53(1):111-6 - PubMed
  13. N Engl J Med. 2003 Feb 6;348(6):518-27 - PubMed
  14. J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 - PubMed
  15. J Infect Dis. 2004 Nov 1;190(9):1685-91 - PubMed
  16. BMC Infect Dis. 2010 Jul 20;10:214 - PubMed
  17. J Infect Dis. 2004 Dec 15;190(12):2070-6 - PubMed
  18. J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 - PubMed
  19. Clin Infect Dis. 2011 May;52(9):1174-81 - PubMed
  20. JAMA. 2002 Apr 24;287(16):2114-9 - PubMed
  21. Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):567-75 - PubMed
  22. Eur J Cancer. 2005 Jan;41(2):297-305 - PubMed
  23. J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 - PubMed
  24. AIDS. 2008 Jun 19;22(10):1203-11 - PubMed
  25. Trends Microbiol. 2011 Mar;19(3):114-20 - PubMed
  26. Ann Intern Med. 2008 May 20;148(10):728-36 - PubMed
  27. MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 - PubMed
  28. J Med Virol. 2010 Aug;82(8):1424-30 - PubMed
  29. Genitourin Med. 1994 Aug;70(4):240-6 - PubMed
  30. Infect Agent Cancer. 2011 Jan 20;6:2 - PubMed
  31. Sex Transm Dis. 2011 Oct;38(10):932-40 - PubMed
  32. Obstet Gynecol Clin North Am. 2008 Dec;35(4):519-36; vii - PubMed
  33. J Natl Cancer Inst. 1990 Sep 19;82(18):1477-84 - PubMed
  34. J Infect Dis. 2001 Sep 15;184(6):682-90 - PubMed
  35. J Infect Dis. 2004 Feb 15;189(4):686-98 - PubMed
  36. Int J Infect Dis. 2009 Jan;13(1):72-80 - PubMed
  37. PLoS One. 2010 Apr 08;5(4):e10094 - PubMed
  38. Cell. 1990 Dec 21;63(6):1129-36 - PubMed
  39. J Gen Virol. 2008 Jun;89(Pt 6):1380-9 - PubMed
  40. J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 - PubMed
  41. Infection. 2008 Feb;36(1):46-53 - PubMed
  42. J Clin Virol. 2012 Jun;54(2):185-9 - PubMed
  43. J Natl Cancer Inst. 2000 May 3;92(9):709-20 - PubMed

Publication Types